We are live on ! Find out more
ACM

Atika Capital Management Portfolio holdings

AUM $796M
1-Year Est. Return 167.57%
This Fund
S&P 500
This Quarter Est. Return
+22.18%
1 Year Est. Return
+167.57%
3 Year Est. Return
+553.47%
5 Year Est. Return
+1,283.26%
10 Year Est. Return
+44,203.78%
AUM
$348M
AUM Growth
+$62.6M
Cap. Flow
+$45.9M
Cap. Flow %
13.19%
Top 10 Hldgs %
43.07%
Holding
103
New
27
Increased
20
Reduced
28
Closed
24

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$12.3M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$4M
3
MZOR
Mazor Robotics Ltd.
MZOR
+$3.63M
4
ALB icon
Albemarle
ALB
+$3.45M
5
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$3.41M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$4.67M
2
ADSK icon
Autodesk
ADSK
+$4.19M
3
MDCO
Medicines Co
MDCO
+$4.13M
4
Z icon
Zillow
Z
+$3.6M
5
SHOP icon
Shopify
SHOP
+$2.96M

Sector Composition

Rank Sector Weight
1 Healthcare 27.47%
2 Communication Services 13.17%
3 Technology 13.06%
4 Consumer Discretionary 5.1%
5 Materials 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLM icon
51
Martin Marietta Materials
MLM
$32.4B
$2.78M 0.8%
13,500
-10,500
-44% -$2.22M
RHT
52
DELISTED
Red Hat Inc
RHT
$2.77M 0.8%
+25,000
New +$2.56M
AERI
53
DELISTED
Aerie Pharmaceuticals
AERI
$2.77M 0.8%
57,000
-8,000
-12% -$436K
MSFT icon
54
Microsoft
MSFT
$3.35T
$2.61M 0.75%
35,000
-15,000
-30% -$1.1M
AKCA
55
DELISTED
Akcea Therapeutics Inc
AKCA
$2.49M 0.72%
+90,000
New +$1.67M
MYOK
56
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.4M 0.69%
+56,000
New +$1.79M
SUM
57
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
$2.39M 0.69%
76,827
-41,765
-35% -$1.19M
CNC icon
58
Centene
CNC
$30.1B
$2.17M 0.62%
44,926
-15,074
-25% -$649K
JAZZ icon
59
Jazz Pharmaceuticals
JAZZ
$16.2B
$2.12M 0.61%
14,500
-4,000
-22% -$605K
ONCE
60
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$2.05M 0.59%
+23,000
New +$1.75M
ROKU icon
61
Roku
ROKU
$21.5B
$1.91M 0.55%
+72,000
New +$1.8M
FWONK icon
62
Liberty Media Series C
FWONK
$25.1B
$1.91M 0.55%
51,714
-81,709
-61% -$2.86M
IMMU
63
DELISTED
Immunomedics Inc
IMMU
$1.89M 0.54%
+135,000
New +$1.35M
HRTX icon
64
Heron Therapeutics
HRTX
$94.1M
$1.45M 0.42%
90,000
+12,000
+15% +$188K
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$1.4M 0.4%
40,000
+11,000
+38% +$149K
EXEL icon
66
Exelixis
EXEL
$14.1B
$1.21M 0.35%
50,000
-15,000
-23% -$399K
BLUE
67
DELISTED
bluebird bio
BLUE
$1.1M 0.32%
618
-1,312
-68% -$1.83M
SLCA
68
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
$1.09M 0.31%
35,000
-32,000
-48% -$927K
ALKS icon
69
Alkermes
ALKS
$8.39B
$1.07M 0.31%
21,000
– –
RGNX icon
70
Regenxbio
RGNX
$648M
$988K 0.28%
+30,000
New +$675K
SGI
71
CALL
Somnigroup International
SGI
$14.1B
$968K 0.28%
+60,000
New +$886K
SAGE
72
CALL
DELISTED
Sage Therapeutics
SAGE
$935K 0.27%
+15,000
New +$1.18M
DBVT
73
DBV Technologies
DBVT
$817M
$848K 0.24%
+2,000
New +$857K
TRIP icon
74
CALL
TripAdvisor
TRIP
$1.65B
$811K 0.23%
20,000
– –
MRNS
75
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$758K 0.22%
+32,250
New +$362K
1 2
3
4 5

Similar funds

AGA
Arkos Global Advisors Houston, Texas $797M AUM 15.28% 1-Year Est. Return
RIM
Rovida Investment Management Grand Cayman, Cayman Islands $797M AUM 111.83% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $797M AUM 4.79% 1-Year Est. Return
CAM
CenterStar Asset Management Chicago, Illinois $797M AUM 28.71% 1-Year Est. Return
Legacy Financial Group (Iowa)
Legacy Financial Group (Iowa) Des Moines, Iowa $795M AUM 12.87% 1-Year Est. Return
LSA
L & S Advisors Los Angeles, California $795M AUM 52.77% 1-Year Est. Return
GWA
Geometric Wealth Advisors Washington, District of Columbia $799M AUM 22.19% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return

Atika Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Atika Capital Management held 103 positions worth $348M, up 22% from $285M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Atika Capital Management deployed $45.9M of net new capital in Q3 2017, opening 27 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 100,000 shares worth $4.54M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 28% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Autodesk, an estimated $4.19M trimmed.

  • Atika Capital Management's largest Q3 2017 buy was Sarepta Therapeutics: 100,000 shares worth $4.54M.
  • Atika Capital Management added most to Intuitive Surgical in Q3 2017, an estimated $12.3M increase.
  • Atika Capital Management's biggest Q3 2017 reduction was Autodesk, cutting an estimated $4.19M.
  • Atika Capital Management fully exited Regeneron Pharmaceuticals in Q3 2017, selling an estimated $4.67M.
  • Atika Capital Management's ten largest holdings make up 43% of its $348M portfolio in Q3 2017.
  • Atika Capital Management opened 27 new positions and closed 24 in Q3 2017.
  • Atika Capital Management's portfolio value rose 22% quarter-over-quarter to $348M.

Based on Atika Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.